Revenue Performance - Total revenue for Q1 2025 increased by 180thousand,or0.361.3 million compared to Q1 2024[4] - Total revenue for Q1 2025 was 61,268,000,aslightincreaseof0.361,088,000 in Q1 2024[24] - Sales revenue decreased to 52,469,000inQ12025from53,307,000 in Q1 2024, representing a decline of 1.6%[24] - Rental revenue increased to 8,799,000inQ12025,up13.17,781,000 in Q1 2024[24] - Lymphedema products accounted for 83% of total revenue in Q1 2025, down from 86% in Q1 2024[27] - The company expects full year 2025 total revenue in the range of 309millionto315 million, representing growth of approximately 5% to 8% year-over-year[11] Profitability - Gross profit for Q1 2025 increased by 1.9million,or445.3 million, with a gross margin of 74% compared to 71% in Q1 2024[5] - Gross profit for Q1 2025 was 45,346,000,anincreaseof4.443,429,000 in Q1 2024[24] - Adjusted EBITDA loss for Q1 2025 was 0.3million,comparedtopositiveAdjustedEBITDAof1.0 million in Q1 2024[9] - Adjusted EBITDA for Q1 2025 was (259,000),adecreaseof1251,033,000 in Q1 2024[28] - The company now expects full year 2025 adjusted EBITDA in the range of 32millionto34 million, compared to adjusted EBITDA of 37.1millionin2024[12]ExpensesandLosses−NetlossforQ12025was3.0 million, or (0.13)perdilutedshare,comparedtoanetlossof2.2 million, or (0.09)perdilutedshare,inQ12024[8]−NetlossforQ12025was2,974,000, compared to a net loss of 2,209,000inQ12024,reflectinga34.73.5 million, or 8%, to 49.9million,primarilyduetoplannedstrategicinvestments[7]−Operatingexpensesroseto49,888,000 in Q1 2025, up 7.4% from 46,393,000inQ12024[24]CashandStockRepurchase−AsofMarch31,2025,thecompanyhad83.6 million in cash and 25.5millionofoutstandingborrowingsunderitscreditagreement[10]−CashattheendofQ12025was83,619,000, a decrease from 94,367,000atthebeginningoftheperiod[26]−Thecompanyrepurchased10.0 million of stock during Q1 2025 under its share repurchase program[6]